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Background: Patients with rheumatoid arthritis (RA) have greater rates of cardiovascular mortality and RA is an
independent cardiovascular risk factor. For the management of cholesterol, the American College of Cardiology/
American Heart Association (ACC/AHA) developed new guidelines for the general population. None of the
European or American guidelines are speciﬁc to RA. The European League Against Rheumatism (EULAR) recom-
mends applying a coefﬁcient to cardiovascular risk equations based on the characteristics of RA. Our objective
was to compare the three different sets of guidelines for the eligibility of statin therapy in RA-speciﬁc population
with very high risk of cardiovascular disease.
Methods and results:We calculated the proportion of patients eligible for statins according to the guidelines of the
European Society of Cardiology (ESC), the Adult Treatment Panel III (ATP-III) and the ACC/AHA in a French cohort
of statin-naïve RA patients at least 40 years age. Of the 547 women and 130men analyzed, statins would be rec-
ommended for 9.1% of thewomen and 26.4% of themen, 15.6% of thewomen and 53.1% of themen, 38.8% of the
women and 78.5% of the men, according to the ESC, ATP-III and ACC/AHA guidelines respectively.
Conclusions: In RA patients, as has been observed in the general population, discordance in risk assessment and
cholesterol treatmentwas observedbetween the three sets of guidelines. The use of the newACC/AHAguidelines
would expand the eligibility for statins and may be applied to RA population a condition at very high risk of car-
diovascular disease.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Rheumatoid Arthritis (RA) leads to an increase in mortality com-
pared with the general population and cardiovascular disease accounts
for approximately half of the death [1–3]. RA itself is an independent
risk factor for cardiovascular disease that carries as much weight as di-
abetes [4–7]. Then, RA should be regarded as a condition at very high, Hôpital G. Montpied, 58 rue
rance.
(A. Tournadre),
tferrand.fr (B. Pereira),
psl.aphp.fr (L. Gossec),
rmontferrand.fr (M. Soubrier),
eliability and freedom from bias
land Ltd. This is an open access articlrisk of cardiovascular disease. In the general population, strategies for
preventing cardiovascular disease are based on calculations of 10-year
cardiovascular mortality risk using the Systematic Coronary Risk Evalu-
ation (SCORE) in Europe and the Framingham score in the United States
on the basis of traditional risk factors. In RA, the increased cardiovascu-
lar risk is only partially explained by traditional risk factors and inﬂam-
mation not included as a parameter in SCORE or Framinghamequations,
may account for the excess cardiovascular risk. The systemic inﬂamma-
tion associated with RA promotes atherogenesis and exacerbates
established cardiovascular risk factors. Other factors associated with
an increased cardiovascular risk in RA are disease duration, rheumatoid
factor or anti-cyclic citrullinated peptide (anti-CCP) positivity, severe
disease with extraarticular manifestations. How to capture the extra
risk beyond the traditional risk factors in clinical practice is a debatede under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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tism (EULAR) guidelines for themanagement of cardiovascular risk rec-
ommend an annual assessment depending on the SCORE equation or
validated national risk equations [9]. The risk score should be thenmul-
tiplied by 1.5 when RA has two of the following three characteristics:
disease progression of over 10 years, positive rheumatoid factor or
anti-CCP, and extra-articular symptoms [9].While the European Society
of Cardiology (ESC) guidelines recommend statin therapy for primary
prevention on the basis of a combined assessment of low-density lipo-
protein cholesterol (LDLc) level and the 10-year risk of cardiovascular
mortality using the SCORE equation [10], the Adult Treatment Panel-III
(ATP-III) guidelines were based on the combination of LDLc and the
10-year risk of coronary heart disease only as calculated with the Fra-
mingham risk calculator [11]. The American College of Cardiology/
American Heart Association (ACC/AHA) guidelines have just been up-
dated and a new equation evaluating the risk of all hard atherosclerotic
cardiovascular disease (ASCVD) in the general populationwas validated
[12]. In a cohort of patients with deﬁnite RA, we calculated the propor-
tion of patients eligible for statins according to the guidelines of the ESC,
ATP-III and ACC/AHA by applying a coefﬁcient of 1.5 to the risk equa-
tions if necessary, as recommended by the EULAR. Our objective was
to compare the three different sets of guidelines for the eligibility of
statin therapy in RA-speciﬁc population with very high risk of cardio-
vascular disease.
1. Methods
1.1. Study population
COMEDRA is a multicenter French cohort study evaluating the impact of nurse-led
programon themanagement of comorbidities in patientswith RA [13]. The study included
the report of pre-existing comorbidities, the presence of risk factors and the implementa-
tion of the recommendation for the detection and/or management of such comorbidities.
Patients with RA according to the 1987 American College of Rheumatology criteria, aged
between 18 and 80 and with disease considered by the treating rheumatologist to have
been stable for at least three months, were recruited from March 2011 to December
2011. Each patient gave their free, informed consent to take part and the local French au-
thorities approved the study. The eligibility for statin therapywas assessed for eachpatient
aged 40 years or older not receiving statins.
1.2. Cardiovascular risk stratiﬁcation
The 10-year risks for cardiovascular mortality (ESC), coronary heart disease (ATP-III)
and ASCVD (ACC/AHA)were calculated for each individual on the basis of the three equa-
tion scores using online calculators [14–16]. A coefﬁcient of 1.5 was applied when a pa-
tient presented two of the following three characteristics: disease progression for over
10 years, rheumatoid factor or anti-CCP positivity and extra-articular signs and symptoms
[9]. The recommended thresholds were used for the application of the European (ESC),
ATP-III and ACC/AHA statin treatment guidelines. Based on each guideline, the patients
were classiﬁed into 3 categories: “no treatment”, “treatment considered”, “recommended
treatment”. eTables 1–3 in the Supplementary data presents the details of these 3 treat-
ment categories by each guideline.
ESC guidelines are based on the SCORE equation, which determines the 10-year car-
diovascularmortality risk of aﬁrst fatal atherosclerotic event including heart attack, stroke
or other occlusive arterial disease [10]. The guidelines were validated in the French popu-
lation. The SCORE equation was determined for each patient using an online calculator
[14] because this is what is used to consider the HDL cholesterol, a major cardiovascular
risk factor which frequently decreases in RA [17]. The other parameters of this equation
are age, gender, tobacco use, systolic blood pressure and cholesterol. This equation validat-
ed in patients 40 to 65 years of age identiﬁes patients with very high (SCORE N 10%), high
(5% b SCORE b 10%) ormoderate (1% b SCORE b 5%) cardiovascular risk [10]. Initiating stat-
in treatment is recommended when cardiovascular risk is N10% and LDL cholesterol is
N1.8 mmol/l (0.7 g/l) and when cardiovascular risk is N5% and b10% and LDL cholesterol
is N2.5mmol/l (1 g/l) [10]. Initiating stainsmay also be considered in patients with cardio-
vascular risk of N10% and LDL cholesterol of b1.8 mmol/l (0.7 g/l), when cardiovascular
risk is N5% and b10% and LDL cholesterol is b2.5 mmol/l (1 g/l), when cardiovascular
risk is N1% and b5% and LDL cholesterol is N2.5 mmol/l (1 g/l) and when cardiovascular
risk b1% and LDL cholesterol is N4.9 mmol/l (1.9 g/l) [10].
ATP-III guidelines are based on 10-year coronary heart disease risk. The risk factors
taken into consideration in this equation are age, sex, tobacco use, HDL-cholesterol, hyper-
tension and blood pressure treatment. The riskwas determinedwith the online calculator
[15]. It is recommended to initiate statins in patients with a calculated risk of N20% when
their LDL cholesterol is N100 mg/dl (2.5 mmol/l), when LDL cholesterol is N130 mg/dl
(3.4 mmol/l) and calculated risk is 10% to 20% and there are two other cardiovascular
risk factors, when LDL cholesterol is N160 mg/dl (4.1 mmol/l), calculated risk is b10%and there are two other cardiovascular risk factors, and when LDL cholesterol is greater
than 190 mg/dl (4.9 mmol/l) [11]. Statin treatment may also be considered in patients
with a calculated risk N20% when LDL cholesterol is b100 mg/dl (2.5 mmol/l), when LDL
cholesterol is 100 to 129 mg/dl (2.5 and 3.4 mmol/l) and calculated risk is 10% to 20%
and there are two other cardiovascular risk factors, and when LDL cholesterol is 160 to
189 mg/dl (3.4–4.9 mmol/l) [11].
ACC/AHA guidelines are based on the 10-year atherosclerotic cardiovascular disease
risk (the Pooled Cohort Equations) that determines the risk of fatal and non-fatal myocar-
dial infarction, other coronary heart disease (CHD)mortality and stroke [12]. The risk was
determined with the online calculator [16]. It is recommended to initiate statins in all
patients with clinical atherosclerotic cardiovascular disease or with elevation of LDL cho-
lesterol ≥190 mg/dl (4.9 mmol/l) [12]. It is recommended to initiate statins in patients
40–75 years of age with diabetes and LDL cholesterol greater than 70 mg/dl, and in pa-
tients with a cardiovascular risk of 7.5% or higher, 40–75 years of age and LDL cholesterol
greater than 70 mg/dl [12]. Statins can be considered in patients whose calculated risk is
5% to 7.5% [12].
1.3. Statistical analyses
Statistical analysis was performed using Stata 13 software (StataCorp LP, College
Station, TX, US). Baseline characteristics were presented as mean (±standard-deviation)
or median (interquartile range) for continuous data (assumption of normality assessed
using the Shapiro–Wilk test) and as the number of patients and associated percentages
for categorical parameters. Comparisons of the three equation scores were made using
the Stuart–Maxwell test for categorical parameters. The tests were two-sided, with a
Type I error set at α= 0.05. Since the SCORE equation was validated for the population
aged 40–65 years, an additional sub-group analysis was performed by age.2. Results
2.1. Study population
There were 970 patients enrolled in the COMEDRA study. Among
this initial population, patients were excluded because they were
receiving a statin (n = 168), were under the age of 40 (N= 49) or be-
cause there were missing data (n = 76). The 677 analyzed patients
weremainlywomen (N=547, 80.8%)with amean RAdisease duration
of 11.4 (6.5–19.8) years (Table 1). The RA characteristics and the cardio-
vascular risks are presented in Table 1 for all patients and in Tables 2 and
3 for patients aged 40–65 and those over the age of 65. The EULAR
coefﬁcient needed to be applied in 59.9% of the patients.
2.2. Treatment recommendations based on the different guidelines
Based on the ESC guidelines, 9.1% of the women and 26.1% of the
men were included in the “treatment recommended” category. The
“treatment considered” group comprised 43.9% of the women and
60.8% of the men and the “no treatment” category 47% of the women
and 13.1% of themen (Fig. 1A, Table 4 and eTable 1 in the Supplementa-
ry data).
Using the ATP-III guideline, 15.5% of the women and 53.1% of the
men were categorized in the “treatment recommended” group, 11.7%
of the women and 18.4% of the men in the “treatment considered”
group and 72.8% of the women and 28.5% of the men in the “no treat-
ment” category (Fig. 1A, Table 4 and eTable 2 in the Supplementary
data).
Based on the ACC/AHA guidelines, the “treatment recommended”
group included 38.8% of the women and 78.5% of the men. The
“treatment considered” group comprised 11.5% of the women and
7.7% of the men, the “no treatment” category 49.7% of the women
and 13.8% of the men (Fig. 1A, Table 4 and eTable 3 in the Supple-
mentary data).
The same differences between the three guidelines were observed
whether considering subjects 40 to 65 years of age or patients over
65 years of age (Fig. 1B and C). In contrast to the SCORE equation,
Framingham risk scoring and the Pooled Cohort Risk Assessment
equation can also be used in patients over the age of 65. For these pa-
tients and according to the ACC/AHA guidelines, all men and 93.2% of
women should receive statin therapy.
Table 1
Characteristics of all patients.
Total
N = 677
Women
N = 547 (80.8%)
Men
N = 130 (19.2%)
Age, years; mean ± SD 58.7 ± 9.4 58.5 ± 9.4 59.4 ± 9.3
Disease course duration, years; median [Q1–Q3] 11.4 [6.5–19.3] 12.7 [7.3–20.2] 7.4 [4.3–13.4]
Positive RF or anti-CCP; n (%) 566/674 (84.0) 454/545 (83.3) 112/129 (86.8)
Erosive RA; n (%) 500/671 (74.5) 409/543 (75.3) 91/128 (71.1)
DAS28 score (ESR); mean ± SD 3.06 ± 1.27 3.17 ± 1.24 2.57 ± 1.28
DAS28 score (CRP); mean ± SD 2.83 ± 1.13 2.89 ± 1.13 2.57 ± 1.06
mHAQ score; mean ± SD 0.40 ± 0.44 0.41 ± 0.45 0.33 ± 0.39
RAID; mean ± SD 2.95 ± 2.03 3.04 ± 2.07 2.54 ± 1.80
Current DMARD; n (%)
None 13 (1.9) 12 (2.2) 1 (0.8)
Biological only 118 (17.4) 94 (17.2) 24 (18.5)
Conventional synthetic only 182 (26.9) 147 (26.9) 35 (26.9)
Biological and synthetic 364 (53.8) 294 (53.7) 70 (53.8)
Current MTX; n (%) 481 (71.0) 389 (71.1) 92 (70.8)
Current corticosteroid intake; n (%) 248 (36.6) 195 (35.6) 53 (40.8)
Current corticosteroid intake (prednisone dose, mg/day; mean ± SD) 5.4 ± 5.3 5.1 ± 5.7 6.3 ± 3.4
Cardiovascular disease, n (%) 35 (5.2) 20 (3.7) 15 (11.6)
Diabetes, n (%) 35 (5.2) 23 (4.2) 12 (9.2)
Diabetes treatment, n (%) 32/35 (91.4) 20/23 (87.0) 12/12 (100.0)
Family history of CHD, n (%) 99 (14.6) 76 (13.9) 23 (17.7)
Smoking, n (%) 106 (15.7) 77 (14.1) 29 (22.3)
Systolic blood pressure (mm Hg); mean ± SD 124.8 ± 16.1 124.0 ± 16.3 128.2 ± 14.8
Diastolic blood pressure (mm Hg); mean ± SD 75.9 ± 11.3 75.5 ± 10.9 77.5 ± 12.5
Antihypertensive, n (%) 195 (28.8) 161 (29.4) 34 (26.2)
Antihypertensive treatment at baseline (n = 195) 182 (93.3) 149 (92.5) 33 (97.1)
Body mass index (kg/m2); mean ± SD 25.1 ± 4.8 24.7 ± 4.8 26.7 ± 4.5
Total cholesterol (g/l); mean ± SD 2.17 ± 0.45 2.19 ± 0.44 2.11 ± 0.47
HDL cholesterol (g/l); mean ± SD 0.67 ± 0.19 0.70 ± 0.18 0.57 ± 0.19
LDL cholesterol (g/l); mean ± SD 1.33 ± 0.38 1.33 ± 0.38 1.35 ± 0.40
Triglyceride (g/l); mean ± SD 1.07 ± 0.65 1.06 ± 0.66 1.12 ± 0.62
Fasting glucose (g/l); mean ± SD 0.97 ± 0.46 0.94 ± 0.40 1.09 ± 0.62
Fasting glucose (g/l) for current corticosteroid intake; mean ± SD 0.96 ± 0.52 0.90 ± 0.43 1.15 ± 0.74
Need to apply the coefﬁcient of 1.5 as recommended by EULAR, n (%) 402/671 (59.9) 340/544 (62.5) 62/127 (48.8)
Table 2
Characteristics of patients 40 to 65 years of age.
Patients 40 to 65 years of age Total
N = 510
Women
N = 415 (81.4%)
Men
N = 95 (18.6%)
Age, years; mean ± SD 54.6 ± 6.8 54.5 ± 6.9 55.1 ± 6.5
Disease course duration, years; median [Q1–Q3] 10.7 [6.1–18.4] 11.4 [6.7–18.8] 7.8 [4.2–13.4]
Positive RF or anti-CCP; n (%) 429/509 (84.3) 347/414 (83.8) 82 (86.3)
Erosive RA; n (%) 366/506 (72.3) 301/412 (73.1) 65/94 (69.1)
DAS28 score (ESR); mean ± SD 2.98 ± 1.26 3.09 ± 1.24 2.48 ± 1.25
DAS28 score (CRP); mean ± SD 2.78 ± 1.11 2.83 ± 1.12 2.55 ± 1.03
mHAQ score; mean ± SD 0.37 ± 0.43 0.38 ± 0.43 0.33 ± 0.40
RAID; mean ± SD 2.88 ± 2.03 2.97 ± 2.08 2.51 ± 1.76
Current DMARD; n (%)
None 10 (1.9) 9 (2.2) 1 (1.1)
Biological only 83 (16.3) 66 (15.9) 17 (17.9)
Synthetic only 135 (26.5) 116 (27.9) 19 (20.0)
Biological and synthetic 282 (55.3) 224 (54.0) 58 (61.0)
Current MTX; n (%) 372 (72.9) 302 (72.8) 70 (73.7)
Current corticosteroid intake; n (%) 183 (35.9) 145 (34.9) 38 (40.0)
Current corticosteroid intake (prednisone dose, mg/day; mean ± SD) 5.3 ± 6.0 5.2 ± 6.6 5.7 ± 3.0
Cardiovascular disease, n (%) 20 (3.9) 11 (2.7) 9 (9.5)
Diabetes, n (%) 22 (4.3) 17 (4.1) 5 (5.3)
Diabetes treatment, n (%) 21/22 (95.5) 16/17 (94.1) 5/5 (100.0)
Family history of CHD, n (%) 76 (14.9) 58 (14.0) 18 (18.9)
Smoking, n (%) 98 (19.2) 70 (16.9) 28 (29.5)
Systolic blood pressure (mm Hg); mean ± SD 122.6 ± 15.5 121.6 ± 15.4 127.2 ± 15.0
Diastolic blood pressure (mm Hg); mean ± SD 75.7 ± 11.4 75.2 ± 10.9 77.7 ± 13.1
Antihypertensive, n (%) 118 (23.1) 96 (23.1) 22 (23.2)
Antihypertensive treatment at baseline (n = 118) 112 (94.9) 91 (94.8) 21 (95.5)
Body mass index (kg/m2); mean ± SD 25.1 ± 4.8 24.8 ± 4.8 26.5 ± 4.2
Total cholesterol (g/l); mean ± SD 2.17 ± 0.43 2.17 ± 0.41 2.16 ± 0.50
HDL cholesterol (g/l); mean ± SD 0.67 ± 0.19 0.69 ± 0.18 0.57 ± 0.20
LDL cholesterol (g/l); mean ± SD 1.31 ± 0.36 1.30 ± 0.34 1.34 ± 0.43
Triglyceride (g/l); mean ± SD 1.04 ± 0.67 1.02 ± 0.66 1.13 ± 0.69
Fasting glucose (g/l); mean ± SD 0.96 ± 0.48 0.93 ± 0.42 1.09 ± 0.67
Fasting glucose (g/l) for current corticosteroid intake; mean ± SD 0.95 ± 0.56 0.92 ± 0.50 1.11 ± 0.76
Need to apply the coefﬁcient of 1.5 as recommended by EULAR, n (%) 296/505 (58.6) 247/413 (59.8) 49/92 (53.3)
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Table 3
Characteristics of patients over 65 years of age.
N65 years-old Total
N = 167
Women
N = 132 (79.1%)
Men
N = 35 (20.9%)
Age, years; mean ± SD 71.0 ± 4.0 70.9 ± 3.9 71.2 ± 4.3
Disease course duration, years; median [Q1–Q3] 14.7 [7.5–22.7] 15.7 [10.3–23.3] 6.5 [4.4–16.8]
Positive RF or anti-CCP; n (%) 137/165 (83.0) 107/131 (81.7) 30/34 (88.2)
Erosive RA; n (%) 134/165 (81.2) 108/131 (82.4) 26/34 (76.5)
DAS28 score (ESR); mean ± SD 3.29 ± 1.27 3.42 ± 1.22 2.82 ± 1.33
DAS28 score (CRP); mean ± SD 2.98 ± 1.18 3.09 ± 1.17 2.61 ± 1.14
mHAQ score; mean ± SD 0.48 ± 0.48 0.53 ± 0.49 0.31 ± 0.36
RAID; mean ± SD 3.14 ± 2.03 3.28 ± 2.04 2.63 ± 1.93
Current DMARD; n (%)
None 3 (1.8) 3 (2.3) 0 (0.0)
Biological only 35 (21.0) 28 (21.2) 7 (20.0)
Synthetic only 47 (28.1) 31 (23.5) 16 (45.7)
Biological and synthetic 82 (49.1) 70 (53.0) 12 (34.3)
Current MTX; n (%) 109 (65.3) 87 (65.9) 22 (62.9)
Current corticosteroid intake; n (%) 65 (38.9) 50 (37.9) 15 (42.9)
Current corticosteroid intake (prednisone dose, mg/day; mean ± SD) 5.5 ± 2.8 4.8 ± 1.9 7.7 ± 3.9
Cardiovascular disease, n (%) 15 (9.0) 9 (6.8) 6 (17.6)
Diabetes, n (%) 13 (7.8) 6 (4.5) 7 (20.0)
Diabetes treatment, n (%) 11/13 (84.6) 4/6 (66.7) 7/7 (100.0)
Family history of CHD, n (%) 23 (13.8) 18 (13.6) 5 (14.3)
Smoking, n (%) 8 (4.8) 7 (5.3) 1 (2.9)
Systolic blood pressure (mm Hg); mean ± SD 131.6 ± 16.1 131.7 ± 16.6 131.0 ± 13.9
Diastolic blood pressure (mm Hg); mean ± SD 76.6 ± 10.9 76.5 ± 11.0 76.9 ± 11.0
Antihypertensive, n (%) 77 (46.1) 65 (49.2) 12 (34.3)
Antihypertensive treatment at baseline (n = 77) 70 (90.9) 58 (89.2) 12 (100.0)
Body mass index (kg/m2); mean ± SD 25.2 ± 4.8 24.7 ± 4.6 27.1 ± 5.3
Total cholesterol (g/l); mean ± SD 2.18 ± 0.49 2.23 ± 0.52 1.97 ± 0.34
HDL cholesterol (g/l); mean ± SD 0.69 ± 0.18 0.72 ± 0.17 0.56 ± 0.15
LDL cholesterol (g/l); mean ± SD 1.39 ± 0.44 1.40 ± 0.47 1.38 ± 0.27
Triglyceride (g/l); mean ± SD 1.15 ± 0.58 1.17 ± 0.62 1.09 ± 0.38
Fasting glucose (g/l); mean ± SD 0.98 ± 0.39 0.94 ± 0.35 1.11 ± 0.48
Fasting glucose (g/l) for current corticosteroid intake; mean ± SD 0.96 ± 0.37 0.87 ± 0.10 1.25 ± 0.68
Need to apply the coefﬁcient of 1.5 as recommended by EULAR, n (%) 106/166 (63.9) 93/131 (71.0) 13 (37.1)
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Our study showed that the proportion of patients with RA requiring
statin therapy varies considerablywith the guidelines, from 9.1 to 38.8%
forwomen and26.2 to 78.5% formen by applying,when necessary, a co-
efﬁcient according to the EULAR guidelines. It is with the new ACC/AHA
guidelines that the greatest number of patients would require statin
treatment. These same differences had already been observed in the
general population [18,19]. The performances of the different cardiovas-
cular risk equations were recently evaluated [19]. In a Dutch cohort of
4209 patient aged 55 years or older, 95.6% of men and 65.8% of
women would require statin treatment according to the ACC/AHA
guidelines, 52% of men and 35.5% of women with the ATP-III guidelines
and 66.1% of men and 39.1% of women with the ESC guidelines [19]. In
this study, the three models overestimated risk with respect to the ob-
served events. Differences between the 3 guidelines involve the fact
that Framingham score takes into account only risk of coronary heart
disease whereas Pooled Cohort and SCORE equations include also
stroke. ESC guidelines do not take into account the increased risk after
65 years-old. Compared with the ATP-III guidelines, the ACC/AHA
guidelines place more importance on 10-year predicted risk than on
LDLc levels, and have greater sensitivity, especially in the elderly
population (N60 years of age) but with less speciﬁcity [20]. Except
in secondary prevention, in all patients with elevation of LDL
cholesterol ≥ 190 mg/dl and in patients with diabetes, new ACC/AHA
guidelines base the recommendation for statin therapy on the solely
threshold of cardiovascular risk of 7.5% rather than on speciﬁc LDL cho-
lesterol targets. Finally, in secondary prevention, ACC/AHA guidelines
recommend statin therapy for all patients whereas some can be catego-
rized as “treatment considered” or “treatment not recommended”with
ATP-III or ESC guidelines.Cardiovascular risk management in RA raises speciﬁc problems. In
contrast to the general population, the risk equations can underestimate
the cardiovascular risk, especially in elderly patients with RA with the
presence of rheumatoid factor and an elevated sedimentation rate [21]
or when the observed risk is low or moderate [22]. Therefore, approxi-
mately 30% of cardiovascular events are observed in patients with a
low calculated risk [22]. This is explained by the fact that the cardiovas-
cular risk observed in RA depends both on RA activity and cardiovascu-
lar risk factors [23,24]. Even if a coefﬁcient is applied, the SCORE
equation underestimates RA cardiovascular risk [25]. Indeed, in a
study of 327 RA patients, only ﬁve patients were reclassiﬁed as high or
very high risk when applying the coefﬁcient suggested by EULAR. In
contrast carotid intima–media thickness N0.90 mm or the presence of
carotid plaques was observed in 63% ofmoderate risk patients, enabling
these patients to be reclassiﬁed as high cardiovascular risk patients [25].
The new Pooled Cohort equation was better than SCORE to identify pa-
tients with high cardiovascular risk when carotid intima–media thick-
ness for the detection of subclinical atherosclerosis was used as the
gold standard test (58% vs 16% respectively, P b 0.0001) [26]. However,
it failed to identify 42% of patients with subclinical atherosclerosis [26].
In addition, inﬂammatory status can induce quantitative and qualitative
changes in lipid proﬁle in RA leading to misinterpretation of lipid levels
[17,27]. The lower impact of the LDLc in the ACC/AHA guidelines
suggests better sensitivity for these guidelines that lipid-proﬁle-based
cardiovascular risk stratiﬁcation in particular when control of inﬂam-
mation is not achieved.
Although cardiovascular disease contributes to half of the mortality
occurring during RA [1], lipid-lowering agents are underused in RA de-
spite management guidelines to reduce LDLc levels as recommended by
ATP III [28,29]. In the present RA cohort, only 17.7% of patients aged 40
to 65 and 25.8% of patients over the age of 65 received a statin, while
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Fig. 1. Treatment recommendations for COMEDRA study participants based on the 2012
ESC, 2004 ATP-III and 2013 ACC/AHA guidelines. A: All patients, B: Age 40–65 years, and
C: Age N65 years.
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ceived a statin. In addition, 5.2% of the patients with a history of cardio-
vascular disease or diabetes warranting statin treatment were not
taking any, regardless of the guidelines. In the general population, statin
therapy is a key factor in reducing cardiovascular risk [30]. There are no
large-scale controlled studies on the effect of statins as primary cardio-
vascular risk prevention in RA. In a Scottish cohort of 430 RA, including
181 statin-exposed and 249 statin-unexposed patients, with a mean
follow-upperiod of 3.90 and 3.14 years, statins reduced total cholesterol
by 16% andwere associated in primary preventionwith reduced cardio-
vascular events (HR: 0.45 [0.20–0.98]) and concomitant decrease in all-
cause mortality (OR: 0.43 [0.20–0.92]) [31]. As secondary prevention,Table 4
Treatment recommendations based on different guidelines (all patients).
ESC ATP-III ACC/AHA P value
Women (n = 547)
Treatment recommended 50 (9.1) 85 (15.5) 212 (38.8) b0.001
Treatment considered 240 (43.9) 64 (11.7) 63 (11.5) b0.001
No treatment 257 (47.0) 398 (72.8) 272 (49.7) b0.001
Men (n = 130)
Treatment recommended 34 (26.1) 69 (53.1) 102 (78.5) b0.001
Treatment considered 79 (60.8) 24 (18.4) 10 (7.7) b0.001
No treatment 17 (13.1) 37 (28.5) 18 (13.8) b0.001the decrease in cholesterol with statins and relapse in MI are identical,
regardless of whether or not the patients have RA, and discontinuing
statins is accompanied by a high risk of stroke [32,33]. Finally, it was
demonstrated that baseline systemic inﬂammation or lipid levels did
not inﬂuence the dose of statin needed to reach LDLc target [34].
Strength of the study includes the application and the comparison of
the 3 different guidelines in a speciﬁc RA population at very high or high
total cardiovascular risk comparable to the risk in patients with diabe-
tes, by introducing a 1.5 multiplication factor depending on RA charac-
teristics. An important limitation is that our study does not provide
information on the agreement for each model between the predicted
and the observed risks.
Our study conﬁrmed in RA the differences observed in the general
population with the three types of guidelines. In the speciﬁc case of
RA, the importance of cardiovascularmortality and the underestimation
of risk by the SCORE and Framingham equations support the use of the
new expanded treatment recommendations of the ACC/AHA. Further
studies are needed to clarify the effect the new guidelines would have
by expanding the proportion of RA patients recommended for therapy.
In addition, a RA-speciﬁc cardiovascular risk model may improve the
cardiovascular risk prediction [35].
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